Da Liangshan, Xu Lin
Department of Thoracic Surgery, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210009, China.
Zhongguo Fei Ai Za Zhi. 2013 Mar;16(3):162-5. doi: 10.3779/j.issn.1009-3419.2013.03.09.
An increasing number of patients with advanced non-small cell lung cancer (NSCLC) have been treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). However, significant differences in response to EGFR-TKIs have been shown among advanced NSCLC patients. Recently, selection of patients was mainly based on EGFR gene mutation detection. Nevertheless, mutation detection is often limited by tumour tissues derivation, technique complexity, high cost, and so on. It is urgent to seek other biological markers to predict efficacy of EGFR-TKIs. Many studies have founded that the EGFR gene polymorphisms are also associated with clinical outcome and prognosis in treatment of advanced NSCLC with EGFR-TKIs. Here, we presented a review discussing the correlation between EGFR gene polymorphisms and the efficacy of EGFR-TKIs in advanced NSCLC.
越来越多的晚期非小细胞肺癌（NSCLC）患者接受了表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）治疗。然而，晚期NSCLC患者对EGFR-TKIs的反应存在显著差异。最近，患者的选择主要基于EGFR基因突变检测。然而，突变检测常常受到肿瘤组织来源、技术复杂性、高成本等因素的限制。迫切需要寻找其他生物标志物来预测EGFR-TKIs的疗效。许多研究发现，EGFR基因多态性也与EGFR-TKIs治疗晚期NSCLC的临床疗效和预后相关。在此，我们发表一篇综述，讨论EGFR基因多态性与EGFR-TKIs治疗晚期NSCLC疗效之间的相关性。
